Harrow has seen sharp swings in recent years, and with the stock last closing at US 28.30, the real question for you today is whether that price still lines up with what the business is generating in sales. Strong headli
Why Is Harrow, Inc. (HROW) Stock Up Today?
Updated Nov 17, 2026 6:30 PM ET · Prev Close $29.09
Primary Move Catalyst & Conviction
67% Signal ConvictionUnusual Call buying detected
Options traders are heavily buying calls on HROW, with 96% of volume in calls. This suggests bullish institutional positioning.
This stock is significantly outperforming its Pharmaceuticals & Therapeutics sector peers, suggesting a stock-specific catalyst.
Market & Sector Relative Strength
HROW outperforming the S&P 500 by +2.35%Options Flow & Execution Desk
Bullish Flow · P/C 0.08Unlock 1 Unusual HROW Options Sweep Strike
See exact institutional strike concentrations, volume-to-OI ratios, and multi-leg payoff blueprints with Tradestie Pro.
Recent HROW Catalyst Headlines
Verified WireNashville, Tenn., Nov. 12, 2026 Globe Newswire -- Harrow Nasdaq HROW , a leading provider of ophthalmic disease management solutions in North America, today announced that management will participate in the following inv
Harrow Inc HROW posted record Q3 2026 revenue of 99.3 million, up 39 year over year, driven by strong branded product growth, while significantly lowering its full-year Adjusted EBITDA outlook.
Record branded sales collided with a cut to profit guidance and a failed trial.
1–3 Day Expected Range & Key Level
45% Follow-ThroughWatch for continuation above $29.72
Technical Regime (HROW)
MIXED MA TREND1-Year Historical Move Analogs
39 EventsSessions in the past year where HROW moved >3.0% up:
Retail & Crowd Sentiment
Very BullishUser on StockTwits reported that Opaleye, a significant shareholder in $HROW, sold more shares during Q3.
About Harrow, Inc.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and no...
Get Instant HROW Catalyst Alerts
Receive an email alert when HROW triggers an unusual volume breakout, options sweep, or rating shift.
Other Liquid Stocks Moving Today
All Today's MoversHROW Session & Catalyst FAQ
Why is HROW stock up today?
Options traders are heavily buying calls on HROW, with 96% of volume in calls. This suggests bullish institutional positioning.
Is HROW stock a buy or sell right now?
Today's session carries a 67% catalyst conviction score on 0.26x relative volume (low participation). Our multi-factor model currently rates HROW as HOLD. Review full valuation, quality, and timing signals on the HROW Buy or Sell Decision Brief →
What is HROW's intrinsic value and expected trading range?
At $29.51, HROW's modeled 1-to-3 session range is $29.13 – $30.61, with a key inflection level at $31.21 (resistance). Compare current price against multi-year cash flow projections in the HROW Intrinsic Value & DCF Model → and Market Cycle Phase Tracker →
What do RSI and moving averages signal for HROW?
RSI at 51.8 reflects constructive bullish momentum. HROW trades at $29.51 relative to its 20-day SMA ($28.67) and 50-day SMA ($30.42), reflecting a mixed moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.